Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
JCO Precision Oncology · 2024-12 · (8)
DOI: 10.1200/po-24-00667 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2024-12. Verfasst von Arnab Basu und 16 weiteren Autor:innen. Beteiligte Einrichtung: O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Circulating Tumor DNA, Kidney Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We evaluated ctDNA status and dynamics during surveillance and as part of TRM with clinical outcomes in both patients with clear cell renal cell carcinoma (ccRCC) and non–clear cell renal cell carcinoma (nccRCC) treated with standard-of-care immunotherapy or targeted therapy regimens. METHODS This was a multicenter retrospective analysis of real-world data obtained from commercial ctDNA testing (Signatera, Natera, Inc) in patients with metastatic RCC. Clinical data were collected on International Metastatic RCC Database Consortium (IMDC) risk category, pathologic subtype, and grade. RESULTS The cohort comprised 92 patients (490 plasma samples) including both clear cell and non–clear cell histological subtypes (ccRCC: 79.3%; nccRCC: 14.1%; unclassified: 6.5%). Most of the patients belonged to the IMDC intermediate-risk category (75%, 69/92). Median follow-up was 10 months (range, 4.2-25.8). ctDNA dynamics were assessed in 56 patients on treatment, and ctDNA status was analyzed in the surveillance cohort (n = 32 patients). Serial ctDNA negativity or clearance correlated with improved progression-free survival (PFS) compared with those who became or were persistently ctDNA positive on therapy (hazard ratio [HR], 3.2; P = .012). In the surveillance cohort, patients with positive ctDNA longitudinally experienced significantly inferior PFS (HR, 18; P = .00026) compared with those who were serially negative. CONCLUSION Collectively, we show that serial ctDNA monitoring provides prognostic information for patients undergoing treatment or surveillance, and our findings demonstrate high concordance between ctDNA status/dynamics and subsequent clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
- Rush University Medical Center, Chicago, IL.
- Natera, Inc, Austin, TX.
- Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
- Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
- Vanderbilt University Medical Center, Nashville, TN.
ORCID-Profile: Arnab Basu, Cherry Au, Carcia Carson, Meenakshi Malhotra, Adam C ElNaggar, Minetta C Liu, James Ferguson Iii, Soroush Rais-Bahrami, Alan Tan
Zitieren
APA
Basu, A., Au, C., Kommalapati, A., Kandala, H., Sudhaman, S., Mahmood, T., Carson, C., Pajak, N., Dutta, P., Calhoun, M., Malhotra, M., ElNaggar, A. C., Liu, M. C., Ferguson Iii, J., Peyton, C., Rais-Bahrami, S., & Tan, A. (2024). Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00667
Vancouver
Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T, et al. Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. 2024. doi:10.1200/po-24-00667
BibTeX
@article{Basu2024,
author = {Basu, Arnab and Au, Cherry and Kommalapati, Ajitha and Kandala, Hyndavi and Sudhaman, Sumedha and Mahmood, Tamara and Carson, Carcia and Pajak, Natalia and Dutta, Punashi and Calhoun, Mark and Malhotra, Meenakshi and ElNaggar, Adam C and Liu, Minetta C and Ferguson Iii, James and Peyton, Charles and Rais-Bahrami, Soroush and Tan, Alan},
title = {Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po-24-00667}
}
EUVIMED